Astral Systems, a Bristol-based deep-tech startup pioneering multi-state fusion technology, has raised £23 million in a first close Series A led by Mercia Ventures, with participation from Tees River, Daphni, Blast Club, Speedinvest, and Playfair. The round supports plans to bring critical medical isotopes to market by early 2027, scale production of its modular Multi-State Fusion (MSF) reactors, and advance fusion research.
Fragile global supply chains for medical radioisotopes pose a significant risk to cancer diagnosis and treatment, with over 50 million nuclear medicine procedures performed each year and demand continuing to rise. Astral Systems addresses this through its proprietary multi-state fusion reactors, which the firm says achieve unmatched performance with greater efficiency and lower cost than traditional configurations. Unlike conventional fusion ventures focused solely on long-term power generation, Astral Systems has multiple Technology Readiness Level 9 (TRL9) fusion reactors operational today. In partnership with McMaster University and the Institute for Energy and Nuclear Research (IPEN) in Brazil, the firm has been working on producing Actinium-225 and Lead-212, two radioisotopes critical to new cancer treatments.
With the new capital, Astral Systems intends to run multiple next-generation compact fusion reactors at full capacity by the end of 2026 at its new facility being developed at the former Berkeley Power Station. The stated goal is to establish the highest-flux, highest-intensity, continuously operable private fusion volumetric neutron source in the world. The firm plans to grow its team from 23 to over 40 employees by the end of 2026 and intends to reach profitability within 2027. Over the following years, Astral Systems intends to manufacture dozens more reactors as it expands applications of its multi-state fusion technology across commercial sectors.
This Series A first close brings total funding for Astral Systems to over £28 million. The firm has already established three commercial fusion facilities and generated more than £3 million in revenue via research contracts utilising MSF technology. NASA Laureate and nuclear physicist Dr Theresa Benyo has recently joined as Chief Research Officer, alongside Chief Scientist Dr Mahmoud Bakr. In partnership with the University of Bristol, Astral Systems has completed over a year of tritium breeder blanket research and recently won a UK grant to explore its technology as a testbed for advanced fission fuels.
We are rewriting how we approach fusion and, in doing so, redefining what it means to be a fusion company. This is evident in our novel technology and its near-term applications in modern medicine, as well as facilitating the search for hybrid energy. With this new funding we can accelerate our ambition of building a profitable, impactful fusion business, and build on the momentum of the past 12 months with the backing of our investors.
We're incredibly proud to have led this investment into Astral Systems and are excited about working with Talmon and Tom. Astral's technology has the potential to transform the manufacturing and supply of medical isotopes, which are vitally important for diagnostic and therapeutic purposes. Astral Systems is a perfect example of the bold ideas that Mercia likes to back.
